Featured Research

from universities, journals, and other organizations

Experimental vaccine protects monkeys against mosquito-borne chikungunya virus

Date:
March 5, 2010
Source:
University of Texas Medical Branch at Galveston
Summary:
Researchers have developed an experimental vaccine for chikungunya virus and successfully tested it in monkeys.

Imagine a mosquito-borne virus that has already infected millions of people in recent outbreaks in South and Southeast Asia, the islands of the Indian Ocean, Africa and northern Italy. Although seldom fatal, it causes highly painful arthritis-like symptoms that can linger for months or even years. It's capable of adapting to spread through a mosquito species common in much of North America. And no vaccine or treatment exists to protect humans from its effects.

Related Articles


The scenario may sound like something dreamed up as a training exercise by public health authorities, but the virus is all too real. Called chikungunya, from an East African tribal word describing the contorted postures of its pain-wracked victims, the pathogen has been the focus of intense scientific interest ever since a 2006 outbreak on the island of La Reunion in the Indian Ocean infected about 266,000 people, killing 260 of them.

Now, researchers at the National Institute of Allergy and Infectious Diseases, the University of Texas Medical Branch at Galveston, Purdue University and Bioqual Inc. have developed an experimental vaccine for chikungunya virus and successfully tested it in monkeys. Described in a paper appearing in the March issue of Nature Medicine, the vaccine is composed of noninfectious "virus-like particles." Although coated with the same proteins that enable chikungunya to pass through cell membranes, the vaccine particles lack the proteins that chikungunya uses to replicate inside cells. They look like chikungunya to the immune systems of rhesus macaques, however, which respond to exposure by generating antibodies that defend the monkeys from infection by the real virus.

"This vaccine did an excellent job of protecting the macaques from chikungunya," said UTMB professor Stephen Higgs, one of the paper's authors. "That it worked so well in a primate model is good news -- these macaques are quite similar to humans in their response to chikungunya, and we badly need to develop an effective human vaccine for this virus."

To create the virus-like particles used in the experimental vaccine, the researchers used genetic engineering techniques to produce the structural proteins that produce the spiky, roughly spherical exterior possessed by chikungunya viruses before they have entered a cell. The proteins then assembled themselves into harmless balls that resembled particles of Sindbis virus -- a relative of chikungunya and a fellow member of the alphavirus genus, which also includes a number of insect-borne viruses capable of causing dangerous encephalitis in humans.

Serum drawn from rhesus macaques injected with the virus-like particles contained substantial levels of antibodies that inactivated chikungunya virus. Two groups of macaques were then inoculated, either with virus-like particles or with a sham solution containing no vaccine. When the researchers challenged the monkeys by injection with chikungunya 15 weeks later, they found that the vaccine had completely protected the animals from the virus.

Dr.Gary Nabel, director of the NIAID's Vaccine Research Center and corresponding author on the Nature Medicine paper, said that the vaccine's effectiveness against chikungunya had led his group to plan follow-up investigations into whether the same approach would work against other alphaviruses, such as Western and Eastern equine encephalitis viruses (both responsible for periodic outbreaks in the United States), and Africa's o'nyong-nyong virus.

Other authors of the Nature Medicine paper included Wataru Akahata, Zhi-Yong Yang, Wing-Pui Kong and Srinivas Rao of the NIAID Vaccine Research Center; Hanne Anderson and Mark G. Lewis of Bioqual Inc., Rockville, Md.; and Siyang Sun, Heather Holdaway and Michael Rossmann of Purdue University. The Intramural Research Program of the NIAID Vaccine Research Center supported this investigation.


Story Source:

The above story is based on materials provided by University of Texas Medical Branch at Galveston. Note: Materials may be edited for content and length.


Journal Reference:

  1. Wataru Akahata, Zhi-Yong Yang, Hanne Andersen, Siyang Sun, Heather A Holdaway, Wing-Pui Kong, Mark G Lewis, Stephen Higgs, Michael G Rossmann, Srinivas Rao & Gary J Nabel. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nature Medicine, 2010; DOI: 10.1038/nm.2105

Cite This Page:

University of Texas Medical Branch at Galveston. "Experimental vaccine protects monkeys against mosquito-borne chikungunya virus." ScienceDaily. ScienceDaily, 5 March 2010. <www.sciencedaily.com/releases/2010/03/100304165856.htm>.
University of Texas Medical Branch at Galveston. (2010, March 5). Experimental vaccine protects monkeys against mosquito-borne chikungunya virus. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2010/03/100304165856.htm
University of Texas Medical Branch at Galveston. "Experimental vaccine protects monkeys against mosquito-borne chikungunya virus." ScienceDaily. www.sciencedaily.com/releases/2010/03/100304165856.htm (accessed October 31, 2014).

Share This



More Plants & Animals News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Watch Baby Goose Survive A 400-Foot Cliff Dive

Watch Baby Goose Survive A 400-Foot Cliff Dive

Buzz60 (Oct. 31, 2014) For its nature series Life Story, the BBC profiled the barnacle goose, whose chicks must make a daredevil 400-foot cliff dive from their nests to find food. Jen Markham has the astonishing video. Video provided by Buzz60
Powered by NewsLook.com
World's Salamanders At Risk From Flesh-Eating Fungus

World's Salamanders At Risk From Flesh-Eating Fungus

Newsy (Oct. 31, 2014) The import of salamanders around the globe is thought to be contributing to the spread of a deadly fungus. Video provided by Newsy
Powered by NewsLook.com
Alcoholic Drinks In The E.U. Could Get Calorie Labels

Alcoholic Drinks In The E.U. Could Get Calorie Labels

Newsy (Oct. 31, 2014) A health group in the United Kingdom has called for mandatory calorie labels on alcoholic beverages in the European Union. Video provided by Newsy
Powered by NewsLook.com
Malaria Threat in Liberia as Fight Against Ebola Rages

Malaria Threat in Liberia as Fight Against Ebola Rages

AFP (Oct. 31, 2014) Focus on treating the Ebola epidemic in Liberia means that treatment for malaria, itself a killer, is hard to come by. MSF are now undertaking the mass distribution of antimalarials in Monrovia. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Plants & Animals

Earth & Climate

Fossils & Ruins

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins